Clinician perceptions and reasons for non-use of guideline-directed medical therapy for heart failure with reduced ejection fraction in the United States

Back

ESC Professional Premium Access

Clinician perceptions and reasons for non-use of guideline-directed medical therapy for heart failure with reduced ejection fraction in the United States

Session: Pharmacotherapy in heart failure

Topic: Pharmacotherapy

Speaker: Professor S. Greene (Durham, US)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Professor Stephen Greene

Duke Clinical Research Institute, Durham (United States of America)

10 presentations

2 followers

7 more presentations in this session

Left ventricular reverse remodeling following initiation of sacubitril/valsartan for heart failure with reduced ejection fraction and low blood pressure

Speaker: Doctor Y. Nishihara (Kobe, JP)

Real world data on adopting guideline directed medical therapy post 2021 ESC HF guidelines and effect on renal function.

Speaker: Mr M. Ferrari (Brescia, IT)

Use of guideline-recommended heart failure drugs in high-, middle- and low-income countries: a systematic review and meta-analysis

Speaker: Associate Professor S. Peters (Utrecht, NL)

Candidacy and predicted efficacy of vericiguat in contemporary heart failure outpatient clinics

Speaker: Doctor B. Soh (Waterford, IE)

Quadruple therapy for heart failure before and after electronic cardiac device implantation - are we hitting our targets?

Speaker: Doctor F. Rode (Zagreb, HR)

Access the full session

Pharmacotherapy in heart failure

Speakers: Professor S. Greene, Doctor Y. Nishihara, Mr M. Ferrari, Associate Professor S. Peters, Doctor B. Soh...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources